Development and evaluation of a novel CAR-T cell therapy against CALR mutant neoplasms

Mutant calreticulin (CALR) represents one of the main oncogenic drivers in myeloproliferative neoplasms (MPNs), making it a promising immunotherapeutic target. In this presentation, Alex Rampotas, MD, University College London, London, UK, discusses the development and evaluation of a novel CAR-T therapy for mutant CALR-driven MPNs. This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.